Browse News
Filter News
Found 808,922 articles
-
Bouncing back from a previous rejection, ImmunityBio on Monday secured the FDA’s green light for its IL-15 superagonist Anktiva for non-muscle invasive bladder cancer.
-
The regulator on Monday slapped Abeona Therapeutics with a Complete Response Letter for its investigational cell therapy pz-cel due to chemistry, manufacturing and controls issues.
-
The U.S. Supreme Court on Monday indicated that it will not hear Vanda Pharmaceuticals’ petition in its patent case against Teva Pharmaceuticals regarding the former’s sleep-wake disorder drug Hetlioz.
-
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
4/23/2024
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
4/23/2024
ImmunityBio, Inc., an immunotherapy company, announced that the U.S. Food and Drug Administration has approved ANKTIVA plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
-
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
4/23/2024
Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million.
-
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes.
-
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
4/23/2024
PharmAbcine, Inc. announced that the Company's U.S. subsidiary, Wincal Biopharm, Inc., will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology, the world's largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States.
-
Vizient conducts first Insight: Cell, Gene, and Specialty Pharmacy Symposium
4/23/2024
Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss the promise and unique challenges of the rapidly expanding market of cell, gene and other advanced therapies.
-
Danaher Reports First Quarter 2024 Results
4/23/2024
Danaher Corporation announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
-
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
4/23/2024
Edgewise Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne).
-
CN Bio Raises $21 Million USD in First Close of Series B Investment Round
4/23/2024
CN Bio, a leading provider of single- and multi-organ microphysiological systems, announced it has raised a $21 million investment in the first close of its Series B fundraising round.
-
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
4/23/2024
Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the company’s Board of Directors.
-
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
4/23/2024
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™.
-
Sapio Sciences Launches New Multimodal Registration Capabilities For Its Lab Informatics Platform
4/23/2024
Sapio Sciences has enhanced its lab informatics platform with new multimodal entity registration capabilities for diverse product types, including small and large molecules and conjugates.
-
The National Kidney Foundation Urges Passage of New Home Dialysis Bill
4/23/2024
The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis.
-
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
4/23/2024
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management.
-
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
4/23/2024
The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that the first patient has been dosed in an investigator-initiated trial with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.
-
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
4/23/2024
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
-
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
4/23/2024
ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung, a non-profit arm of Else Kröner-Fresenius Foundation, published the successful track record of its latest funding projects.